Conditions: Cancer
Keywords: GSK1120212 BRAF Inhibitor melanoma MEK Inhibitor
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 97
Healthy volunteers: no

Brief summary:
MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhibitor of MEK activation and kinase activity.

Detailed description:

Arms:
arm 1: Subjects who have had previous treatment with a BRAF inhibitor. arm 2: Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.

Interventions: intervention 1: GSK1120212
Intervention descriptions: intervention 1: Daily oral dosing

Protocol document: